Medifast (MED) Given Media Impact Score of 0.17
News headlines about Medifast (NYSE:MED) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Medifast earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the specialty retailer an impact score of 46.1061401380404 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Weight Loss Services Market – Detailed Analysis of Current Industry Figures with Forecasts Growth By (pressbox.co.uk)
- Medifast, Inc. : MED-US: Dividend Analysis : September 22nd, 2017 (record date) : By the numbers : October 10, 2017 (finance.yahoo.com)
- Top Social Media Marketing Agency Awards Granted for October 2017 by 10 Best SEO (consumerelectronicsnet.com)
- Weight Loss Services Market – NextGen Technological Advancements, Professional Survey and Future Industry Trends : 2023. (medgadget.com)
A number of brokerages recently weighed in on MED. BidaskClub upgraded shares of Medifast from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Sidoti restated a “neutral” rating and set a $55.00 target price (up previously from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Finally, DA Davidson began coverage on shares of Medifast in a research report on Wednesday, August 16th. They set a “buy” rating for the company.
Medifast (NYSE:MED) last released its quarterly earnings results on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.10. Medifast had a net margin of 8.62% and a return on equity of 24.25%. The firm had revenue of $75.70 million for the quarter, compared to analysts’ expectations of $71.96 million. During the same quarter last year, the company earned $0.63 EPS. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 9th. Shareholders of record on Friday, September 22nd will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $1.28 annualized dividend and a yield of 2.07%. Medifast’s dividend payout ratio (DPR) is presently 64.32%.
COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/12/medifast-med-given-media-impact-score-of-0-17.html.
Medifast Company Profile
Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.
Receive News & Stock Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related stocks with our FREE daily email newsletter.